Search research articles
Contact Us
Filters
Showing results (81-90 of 232) with videos related to
Page
of 24
Sort By:
Journal of the National Cancer Institute
|
October 15, 2011
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials
Greg Yothers, Daniel J Sargent, Norman Wolmark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2003
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Harry D Bear, Stewart Anderson, Ann Brown, et al.
Investigational New Drugs
|
June 15, 2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
Sheri K Dennison, Samuel A Jacobs, John W Wilson, et al.
Breast Cancer Research and Treatment
|
August 16, 2015
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29
Judith-Anne W Chapman, Joseph P Costantino, Bin Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2009
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
Lajos Pusztai, Jong-Hyeon Jeong, Yun Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Harold J Burstein, Martine J Piccart-Gebhart, Edith A Perez, et al.
Clinical Colorectal Cancer
|
March 29, 2021
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients
Ofer Margalit, Ben Boursi, Manel Rakez, et al.
Journal of the National Cancer Institute
|
June 6, 2002
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
Soonmyung Paik, John Bryant, Elizabeth Tan-Chiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07
Beth A Zamboni, Greg Yothers, Mehee Choi, et al.
NPJ Breast Cancer
|
November 21, 2018
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Charles E Geyer, Gong Tang, Eleftherios P Mamounas, et al.
Page
of 24
Search research articles
Search
Showing results (81-90 of 232) with videos related to
Sort By:
Page
of 24
Journal of the National Cancer Institute
|
October 15, 2011
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials
Greg Yothers, Daniel J Sargent, Norman Wolmark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2003
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Harry D Bear, Stewart Anderson, Ann Brown, et al.
Investigational New Drugs
|
June 15, 2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
Sheri K Dennison, Samuel A Jacobs, John W Wilson, et al.
Breast Cancer Research and Treatment
|
August 16, 2015
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29
Judith-Anne W Chapman, Joseph P Costantino, Bin Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2009
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
Lajos Pusztai, Jong-Hyeon Jeong, Yun Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Harold J Burstein, Martine J Piccart-Gebhart, Edith A Perez, et al.
Clinical Colorectal Cancer
|
March 29, 2021
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients
Ofer Margalit, Ben Boursi, Manel Rakez, et al.
Journal of the National Cancer Institute
|
June 6, 2002
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
Soonmyung Paik, John Bryant, Elizabeth Tan-Chiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07
Beth A Zamboni, Greg Yothers, Mehee Choi, et al.
NPJ Breast Cancer
|
November 21, 2018
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Charles E Geyer, Gong Tang, Eleftherios P Mamounas, et al.
Page
of 24